DOI: 10.36347/sjams.2020.v08i05.033

Pages: 1335-1338

Aims & objectives: Tumor grading is a significant predictor for clinical outcome of diffuse gliomas. It affects the treatment and prognosis of the patient. The aim of the present study is evaluation of MIB-1 labelling index (LI) in grading diffuse gliomas. Material & Methods: Our study included 50 cases which were diagnosed as diffuse gliomas on H&E staining. Then immunohistochemistry was done for evaluation of MIB-1 labelling index. Grading of tumor was done according to 2016 World Health Organization classification. Result: On H&E, out of 50 cases 17 were diffuse astrocytomas, 4 anaplastic astrocytomas, 18 glioblastomas, 4 oligodendrogliomas and 7 anaplastic oligodendrogliomas cases were diagnosed on H & E examination. Then IHC was done for the evaluation of MIB1 labelling index and it was found that, out of 17 diffuse astrocytomas, 4 were upgraded to anaplastic astrocytomas and out of 4 oligodendrogliomas, 2 were upgraded in higher grade anaplastic oligodendrogliomas because of increased MIB1. Conclusion: MIB-1Labelling index is used as an effective tool in assessing proliferative index in diffuse gliomas and also as an important prognostic indicator supplementing the standard histopathological assessment. Present study demonstrates the usefulness of MIB-1 labelling index in diffuse gliomas for accuracy of grading the tumor. Exact grading is important for treatment and affects the prognosis of the patient.